ERBB2 and gastric cancer: Moreover, HER2 is overexpressed and amplified in ≈20% of gastric cancer (GC) patients, where it is associated with a poor prognosis and is currently recognized as a new diagnostic factor and novel therapeutic target.[14, 15, 16] Accordingly, HER2 is recognized as the first target for cancer therapy and assessing the HER2 status in GC tissue has become a routine approach to these lesions.[15]